
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
NOVOb | Copenhagen | DKK | Real-time | |
NOVOBc | BATS Europe | DKK | Delayed | |
NVO | NYSE | USD | Real-time | |
0QIU | London | DKK | Real-time | |
NVON | Mexico | MXN | Delayed | |
NOVCb | Frankfurt | EUR | Delayed | |
NOVCb | Xetra | EUR | Delayed | |
NOVCb | Dusseldorf | EUR | Delayed |
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Name | Age | Since | Title |
---|---|---|---|
Helge Lund | 61 | 2017 | Independent Chairman of the Board |
Thomas Rantzau | 51 | 2018 | Employee Representative Non-Independent Director |
Andreas Fibig | 61 | 2018 | Independent Director |
Henrik Poulsen | 56 | 2021 | Vice Chairman of the Board |
Laurence M. Debroux | 54 | 2019 | Independent Director |
Liselotte Hyveled | 57 | 2022 | Employee Representative Director |
Mette Bojer Jensen | 48 | 2014 | Employee Non-Independent Representative Director |
Jesper Thorning | - | 2018 | Substitute Director |
Elisabeth Dahl Christensen | 58 | 2022 | Employee Representative Director |
Anders Kaae | - | 2018 | Substitute Director |
Martin W. MacKay | 67 | 2018 | Independent Director |
Sylvie L. Gregoire | 62 | 2015 | Independent Director |
Tanja Villumsen | 43 | 2018 | Substitute Director |
Karina Bonde Lenau | - | 2018 | Substitute Director |
Christina Law | 56 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review